STOCK TITAN

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Overview of Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc. is a commercial-stage medical device company specializing in advanced foot and ankle surgical solutions. With a primary focus on 3D bunion correction and the treatment of complex midfoot deformities, the company harnesses breakthrough technologies to improve surgical practices and patient outcomes. Its innovative Lapiplasty 3D Bunion Correction procedure is designed to address the root cause of bunion deformities by correcting misalignments in all three planes, setting a new benchmark in surgical care for bunion patients.

Core Business and Technological Innovation

At its core, Treace Medical Concepts operates within the high-growth niche of orthopaedic medical devices. The company designs, manufactures, and markets a range of products that include sophisticated instruments, implants, and surgical techniques aimed at reproducibly correcting bunion and midfoot deformities. Its patented procedures signify a significant evolution in musculoskeletal correction by incorporating 3D surgical methodologies. This approach not only accentuates precision and reproducibility but also facilitates faster patient recovery and reduced post-operative complications.

Market Position and Value Proposition

Treace is strategically positioned within a market valued in the billion-dollar range, where the demand for improved surgical interventions is constant. The company extracts value from its innovative product portfolio by providing surgeons with instrumented systems that enhance the standard of care in bunion and midfoot correction. This is achieved through an innovation-driven, high-velocity approach that upholds ethical and high-quality standards—a commitment that resonates well with the company’s core mission of enhancing patient care while managing healthcare costs effectively.

Operational Excellence and Industry Impact

Operating as a single business segment, Treace Medical Concepts integrates research, design, manufacturing, and marketing under a unified strategy. Its operations are geared towards ensuring that each device and technique offers reproducible, high-quality outcomes. The company’s diverse product suite, which includes not only the flagship Lapiplasty system but also complementary systems such as the Adductoplasty Midfoot Correction and SpeedPlate Rapid Compression Implants, exemplifies its comprehensive approach. These innovations empower foot and ankle surgeons to achieve consistent surgical outcomes, making the company a pivotal entity in the transformation of orthopaedic surgery.

Commitment to Quality and Ethical Standards

Embedded in the company’s operational ethos is a commitment to the highest standards of ethical conduct and clinical excellence. Treace Medical Concepts is dedicated not only to advancing surgical technology but also to ensuring that every procedural improvement translates into better patient experiences and reduced long-term healthcare costs. Its robust portfolio of clinical studies and ongoing research efforts provide a critical evidence base that reinforces the efficacy and safety of its procedural innovations.

Understanding the Product Suite

The Lapiplasty 3D Bunion Correction System represents a quantum leap in bunion surgery by systematically addressing the true underlying anatomical misalignments. This system is complemented by other instrumented solutions designed for minimally invasive correction, broadening the spectrum of surgical options available to practitioners. These products underscore the company’s philosophy of integrating advanced technology with rigorous clinical validation to transform the standard of care in orthopaedic procedures.

Competitive Landscape and Surgical Community Engagement

Within a competitive market landscape, Treace distinguishes itself through its sole focus on surgical correction of bunion and related midfoot deformities. Unlike competitors that rely on conventional methods, Treace’s emphasis on complete 3D correction offers a reproducible and scalable solution. The company actively engages with the surgical community through conferences, clinical presentations, and training events, thereby reinforcing its technical authority and contributing to knowledge sharing in the field.

Concluding Insights

Treace Medical Concepts, Inc. embodies the intersection of clinical innovation and operational excellence, contributing substantively to the evolution of foot and ankle surgical practices. Its methodical approach to product development and ethical operational standards makes it a reliable source of transformative surgical technology. For professionals seeking detailed insights into advanced orthopaedic solutions, the company’s offerings provide a comprehensive overview of modern procedural innovations grounded in proven clinical methodologies.

Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) has announced participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 am ET. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat. The event aims to highlight Treace's advancements in treating hallux valgus (bunions) through their patented Lapiplasty® 3D Bunion Correction™ system and the recently introduced Adductoplasty™ Midfoot Correction System, which addresses complex foot deformities and enhances patient recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported Q3 2021 revenue of $21.6 million, marking a 52% increase year-over-year and a 4.7% sequential rise. The gross margin improved to 80.4%, up 80 basis points from the previous year. Key developments included the launch of the Adductoplasty™ System and positive interim data from the ALIGN3D™ clinical study, which showed low recurrence rates post-surgery. Despite pandemic challenges, the firm reaffirms its 2021 revenue guidance of $90 million to $95 million, projecting 57% to 65% growth over 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced the granting of U.S. Patent No. 11,147,590 for its bunion surgery method on October 19, 2021, enhancing its patent coverage in bunion correction techniques. This marks the company's 30th U.S. patent, expanding its innovative portfolio initiated in 2014. The new patent complements U.S. Patent No. 10,945,764, granted in March 2021. Treace’s ongoing R&D efforts aim to address patient needs, with over 60 pending patent applications globally, including over 30 in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.18%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (TMCI) has announced the release date for its financial results for Q3 2021, scheduled for November 4, 2021, after the trading day ends. A conference call will follow at 4:30 p.m. ET to discuss the financials. Treace, which specializes in orthopaedic devices for bunion treatment, features the patented Lapiplasty® 3D Bunion Correction™ system, aimed at addressing the root causes of bunions and improving patient recovery. An archived webcast of the call will be available on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced the appointments of Betsy Hanna and Deepti Jain to its Board of Directors as of October 1, 2021. With extensive healthcare experience, both aim to guide the company through its growth phase, particularly focusing on the Lapiplasty® system and the new Adductoplasty™ Midfoot Correction System. Chairman James T. Treace expressed confidence in their ability to enhance the board's expertise and drive market penetration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
management
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) has initiated the Mini3D Lapiplasty clinical study, focusing on the Lapiplasty Mini-Incision System for bunion correction. The study aims to evaluate outcomes based on 3D correction with smaller incisions (3.5cm) compared to traditional methods. The primary measure of success will be the recurrence of hallux valgus within 24 months. The study will involve up to 200 patients across 20 centers, building on the previous ALIGN3D study, which has enrolled 173 patients and will conclude in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced positive interim findings from the ALIGN3D™ clinical study on their Lapiplasty® 3D Bunion Correction™ procedure at the 2021 AOFAS Annual Meeting. The study, involving 151 participants, reported an average early weight-bearing return at 8.3 days, significant pain reduction, and a low recurrence rate of only 0.9% at 12 months. Patients also returned to work within 4 weeks and full activity within 4.1 months. Treace continues to strengthen its clinical evidence supporting the Lapiplasty® System, aimed at enhancing bunion surgery outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) has launched the Adductoplasty™ System, a comprehensive approach for midfoot deformity correction in bunion patients. This system combines implants and precision instruments to ensure consistent realignment and stabilization of the midfoot, which affects up to 30% of hallux valgus cases. CEO John T. Treace highlighted the system's potential to enhance treatment for patients with combined bunion and midfoot issues, addressing a market gap in surgical solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.27%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark Hair will join a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at approximately 4:15 PM ET. This discussion will focus on the company’s innovative Lapiplasty® 3D Bunion Correction™ procedure, designed to improve surgical treatment for bunions. A live webcast and replay will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $7.75 as of April 4, 2025.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 466.5M.

What is the core focus of Treace Medical Concepts, Inc.?

Treace Medical Concepts, Inc. specializes in the design, manufacture, and marketing of advanced surgical devices for correcting bunion and related midfoot deformities using 3D correction methodologies.

How does the Lapiplasty 3D Bunion Correction procedure work?

The procedure is designed to correct bunion deformities in all three planes by addressing the underlying anatomical misalignments, thereby restoring joint stability and enabling a reproducible surgical outcome.

What products are included in Treace's portfolio?

The company's portfolio includes the flagship Lapiplasty system, the Adductoplasty Midfoot Correction System, and the SpeedPlate Rapid Compression Implants among other instrumented surgical solutions.

Who are the primary customers for Treace Medical Concepts’ products?

The primary customers include foot and ankle surgeons, orthopedic physicians, ambulatory surgery centers, and hospitals aiming to improve surgical outcomes for bunion and midfoot deformities.

How does Treace differentiate itself from competitors?

Treace differentiates itself by focusing exclusively on 3D surgical correction for bunions, offering a comprehensive suite of innovative, reproducible instrumented systems that set new standards in the industry.

What is the significance of Treace's innovation-driven approach?

Their approach ensures that every product is developed with a focus on clinical evidence and reproducibility, which helps enhance surgical outcomes, reduce complications, and improve overall patient care.

How does Treace support the surgical community?

Treace engages with the surgical community through conferences, clinical studies, and training events, providing updated research findings and technical insights that assist surgeons in adopting advanced surgical methods.
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

466.51M
45.36M
26.04%
60.61%
4.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA